Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?

Which of these 3 pharmaceutical companies should you add to your portfolio? Genus plc (LON: GNS), Dechra Pharmaceuticals plc (LON: DPH) or GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have disappointed in the last year, it has not been the same story for a number of its pharmaceutical rivals. In fact, shares in Genus (LSE: GNS) and Dechra (LSE: DPH) have soared in the last 12 months by 35% and 55% respectively, which is a much healthier return than GlaxoSmithKline’s fall of 6%.

Does this mean, then, that Genus and Dechra are better buys that GlaxoSmithKline? Or, is their larger peer now better value for long term investors?

Margin Of Safety

Suffice to say, it is rare to find a pharmaceutical company that offers a wide margin of safety. That’s even more the case when comparing them to the wider market, since they tend to offer stronger growth in the long run, while their lack of strong correlation to the macroeconomic outlook marks them out as strong defensive plays. So, while all three companies trade at premiums to the FTSE 100, their margins of safety still differ somewhat.

For example, Genus and Dechra currently trade on price to earnings (P/E) ratios of 25.6 and 26.1 respectively, which are significantly higher than the FTSE 100’s P/E ratio of around 16. Certainly, both companies are set to increase their bottom lines at a much faster rate than the wider index, with growth of 16% in the current year and 12% next year pencilled in for Genus. Meanwhile, Dechra is expected to grow its profit by 8% this year and 11% in the following year.

The problem, though, is that these above average growth rates appear to be adequately priced in – especially after their aforementioned share price rises in the last year. As such, there is little margin of safety, which could mean that share price growth is not as impressive as the market is currently anticipating.

GlaxoSmithKline, of course, is lacking significant growth appeal over the next couple of years. In fact, its bottom line is forecast to fall by 4% this year before recovering by 3% next year. So, compared to Genus and Dechra, it is expected to post disappointing results. However, GlaxoSmithKline trades on a much lower rating than its two smaller peers, with it having a P/E ratio of just 16.8. This indicates that if the company is able to deliver on the efficiencies it has planned and which are set to catalyse its bottom line, its valuation has scope to move substantially upwards.

Total Return

Of course, with sales and earnings of pharmaceutical companies being relatively volatile, an income element to total return can be highly worthwhile for investors. In this space, GlaxoSmithKline is the clear winner of the three companies, since it has a dividend yield of 5.3% at the present time. This compares favourably to Genus and Dechra, which have yields of just 1.4% and 1.6% respectively.

And, looking ahead, the total return from GlaxoSmithKline could be higher than that of Genus or Dechra, since it offers a much cheaper share price. And, from next year, it is expected to return to growth, which could act as a catalyst on investor sentiment. So, while Genus and Dechra have massively outperformed GlaxoSmithKline in the last year, the tables could turn for investors taking a long term view.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

The National Grid share price just plunged another 10%. Time to buy?

The National Grid share price is one of the FTSE 100's most stable, and nothing much happens to it? Well,…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Up 15% in 3 months, but I still won’t touch Vodafone shares with a bargepole

Harvey Jones has been shunning Vodafone shares for years. The FTSE 100 stock is finally showing signs of life, but…

Read more »

Growth Shares

This UK stock could be like buying Nvidia in 2021

Jon Smith thinks he's missed the boat with Nvidia shares, but flags up a UK stock that has some very…

Read more »

Businesswoman calculating finances in an office
Investing Articles

The FTSE 100’s Intertek delivers a bullish update — can the share price soar?

I’d describe Intertek as a quality business with a decent dividend income, but will the share price shoot the lights…

Read more »

Market Movers

Up another 10% yesterday, how high can the Nvidia share price go?

Jon Smith talks through the latest results but flags up why further gains could be harder to come by for…

Read more »

Investing For Beginners

Down 43% in a year, I think this value stock is primed for a comeback

Jon Smith flags up why a FTSE 250 share has fallen so much in the recent past, but explains why…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Nvidia stock is stupidly expensive. Or is it?

Nvidia stock's up over 2,000% in the past five years. Christopher Ruane explains why it could be wildly overvalued --…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

The FTSE 100 stock I’ve been buying this week

Stephen Wright thinks the FTSE 100 slipping back this week has offered an opportunity in one of the highest-quality UK…

Read more »